Table 3 Association between change in IFNγ plasma level and clinical outcomes in the four subgroups:

From: Natural killer cell activity in metastatic castration resistant prostate cancer patients treated with enzalutamide

Groups

OS

rPFS

TTT

HR (95% CI)

P value

HR (95% CI)

P value

HR (95% CI)

P value

1

1

 

1

 

1

 

2

5.02 (1.70–14.82)

0.003

6.83 (2.62–17.77)

 < 0.001

7.05 (2.69–18.49)

 < 0.001

3

1.33 (0.48–3.73)

0.581

1.77 (0.74–4.22)

0.196

1.46 (0.58–3.68)

0.378

4

1.12 (0.46–2.71)

0.798

1.79 (0.89–3.63)

0.101

1.54 (0.76–3.13)

0.199

Back to article page